Osimertinib in first-line treatment-is a comparison not proof?

被引：2
|
作者：
Cadranel, Jacques [1 ,2 ,3 ]
机构：
[1] Hop Tenon, AP HP, Chest Dept, Paris, France
[2] Hop Tenon, AP HP, Expert Ctr Thorac Oncol, Paris, France
[3] Pierre & Marie Curie Univ Paris 6, Paris, France
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2018年 / 6卷 / 03期
关键词：
CELL LUNG-CANCER; OPEN-LABEL; EGFR MUTATIONS; ASIAN PATIENTS; SURVIVAL-DATA; PHASE-III; AFATINIB; GEFITINIB; ERLOTINIB; CHEMOTHERAPY;
D O I：
10.21037/atm.2017.12.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
    Starrett, J. H.
    Guernet, A.
    Cuomo, M. E.
    Poels, K.
    van Rosenburgh, I. K. van Alderwerelt
    Nagelberg, A.
    Farnsworth, D.
    Price, K.
    Khan, H.
    Ashtekar, K. D.
    Gaefele, M.
    Ayeni, D.
    Stewart, T. F.
    Kuhlmann, A.
    Kaech, S. M.
    Unni, A. M.
    Homer, R.
    Lockwood, W. W.
    Michor, F.
    Goldberg, S. B.
    Lemmon, M. A.
    Smith, P.
    Cross, D.
    Politi, K.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S36 - S36
  • [32] Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
    Starrett, Jacqueline H.
    Guernet, Alexis A.
    Cuomo, Maria Emanuela
    Poels, Kamrine E.
    van Rosenburgh, Iris K. van Alderwerelt
    Nagelberg, Amy
    Farnsworth, Dylan
    Price, Kristin S.
    Khan, Hina
    Ashtekar, Kumar Dilip
    Gaefele, Mmaserame
    Ayeni, Deborah
    Stewart, Tyler F.
    Kuhlmann, Alexandra
    Kaech, Susan M.
    Unni, Arun M.
    Homer, Robert
    Lockwood, William W.
    Michor, Franziska
    Goldberg, Sarah B.
    Lemmon, Mark A.
    Smith, Paul D.
    Cross, Darren A. E.
    Politi, Katerina
    CANCER RESEARCH, 2020, 80 (10) : 2017 - 2030
  • [33] OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC
    不详
    CANCER DISCOVERY, 2017, 7 (10) : 1061 - 1061
  • [34] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [35] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers Reply
    Schoenfeld, Adam J.
    Yu, Helena A.
    JAMA ONCOLOGY, 2020, 6 (12) : 1983 - 1983
  • [36] Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
    Jori, Balazs
    Schatz, Stefanie
    Kaller, Len
    Kah, Bettina
    Roeper, Julia
    Ramdani, Hayat O.
    Diehl, Linda
    Hoffknecht, Petra
    Grohe, Christian
    Griesinger, Frank
    Tiemann, Markus
    Heukamp, Lukas C.
    Falk, Markus
    CANCERS, 2021, 13 (12)
  • [37] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [38] Successful osimertinib retreatment after extremely early onset severe pneumonitis in first-line treatment of lung adenocarcinoma
    Ahn, June Hong
    THORACIC CANCER, 2020, 11 (09) : 2713 - 2716
  • [39] BUDGET IMPACT OF AFATINIB VS OSIMERTINIB IN FIRST-LINE TREATMENT OF EGFR COMMON MUTATION POSITIVE NSCLC IN CHINA
    Yan, J. Z.
    Gong, X. L.
    Zhao, J.
    Shao, R.
    Zhang, Y. J.
    Hong, G.
    Xue, N.
    Mu, S.
    VALUE IN HEALTH, 2020, 23 : S49 - S49
  • [40] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
    Robinson, N. D.
    Zhan, P.
    Udelsman, B.
    Boffa, D. J.
    Goldberg, S. B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
12345